Kondrat Jason, Sultana Nishat, Zangi Lior
Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Methods Mol Biol. 2017;1521:127-138. doi: 10.1007/978-1-4939-6588-5_8.
Cardiac gene therapy shows tremendous promise in combating the growing problem of heart disease. Modified mRNA (modRNA) is a novel gene delivery system used in vitro or in vivo to achieve transient expression of therapeutic proteins in a heterogeneous population of cells. Incorporation of specific modified nucleosides enables modRNA to be translated efficiently without triggering antiviral and innate immune responses. ModRNA has been shown to be effective at delivering short-term robust gene expression to the heart and its use in the field of cardiac gene therapy is expanding. Here, we describe a stepwise protocol for the synthesis of modRNA for in vivo myocardial delivery.
心脏基因治疗在应对日益严重的心脏病问题方面显示出巨大的前景。修饰的信使核糖核酸(modRNA)是一种新型基因递送系统,可在体外或体内使用,以在异质细胞群体中实现治疗性蛋白质的瞬时表达。掺入特定的修饰核苷可使modRNA有效翻译,而不会触发抗病毒和先天免疫反应。已证明modRNA可有效地将短期强大的基因表达递送至心脏,并且其在心脏基因治疗领域的应用正在不断扩大。在此,我们描述了一种用于体内心肌递送的modRNA合成的逐步方案。